Table 2.
Lung perfused surface areas and Pa at start and end of experimental protocols
|
PS, ml/min |
Pa, Torr |
|||
|---|---|---|---|---|
| Start | End | Start | End | |
| NQO1+/+ | 1.80 ± 0.09 | 1.75 ± 0.25 | 6.6 ± 0.5 | 6.2 ± 0.4 |
| NQO1+/− | 1.68 ± 0.08 | 1.50 ± 0.14 | 6.5 ± 0.7 | 6.9 ± 0.8 |
| NQO1−/− | 1.59 ± 0.08 | 1.60 ± 0.09 | 6.7 ± 0.7 | 6.9 ± 0.6 |
Values are means ± SE for lungs in Fig. 4 study before and after duroquinone (DQ) and DQ + dicumarol infusions. There were no significant differences in permeability-surface area product (PS) or perfusion pressure (Pa) between genotypes or at start and end of experimental protocol.